The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas

Table 3 Multiple regression results

variable	regression coefficient	95% CI	t statistic	P
post-TMZ	0.22	−0.070 to 0.51	1.5	0.13
**IDH1mutant**	0.15	0.0020 to 0.30	2	0.047
WHO grade	0.097	−0.036 to 0.23	1.5	0.15
**MGMTmethylated**	0.072	−0.051 to 0.19	1.2	0.25
astrocytic	0.031	−0.22 to 0.29	0.24	0.81
male	0.017	−0.091 to 0.13	0.32	0.75
age	0.00021	−0.0041 to 0.0045	0.099	0.92
recurrent	−0.038	−0.32 to 0.24	0.27	0.79

Variables are listed from largest to smallest regression coefficients, relative to hypermutation. N = 93 tumors (cases without MGMT data were excluded, as well as hypermutated tumor #2 since it came from the same patient as tumor #1, see Additional file 1: Tables S1 and S2). TMZ temozolomide. Multiple R² = 0.26, df = 84

ISSN: 2051-5960